Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system.
Not only have they discovered a method of successfully culturing the cancer cells from blood samples taken using Parsortix, they have also designed a work flow for the process.
Original Article: ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'